First-line therapy in ovarian cancer trials

Tate Thigpen; Andreas DuBois; Jessica McAlpine; Philip DiSaia; Keiichi Fujiwara; William Hoskins; Gunnar Kristensen; Robert Mannel; Maurie Markman; Jacobus Pfisterer; Michael Quinn; Nick Reed; Ann MarieSwart; Jonathan Berek; Nicoletta Colombo; Gilles Freyer; Dolores Gallardo; Marie Plante; Andres Poveda; Lawrence Rubinstein; Monica Bacon; Henry Kitchener; Gavin C E Stuart

doi:10.1097/IGC.0b013e31821ce75d

First-line therapy in ovarian cancer trials

Tate Thigpen, Andreas DuBois, Jessica McAlpine, Philip DiSaia, Keiichi Fujiwara, William Hoskins, Gunnar Kristensen, Robert Mannel, Maurie Markman, Jacobus Pfisterer, Michael Quinn, Nick Reed, Ann MarieSwart, Jonathan Berek, Nicoletta Colombo, Gilles Freyer, Dolores Gallardo, Marie Plante, Andres Poveda, Lawrence RubinsteinMonica Bacon, Henry Kitchener, Gavin C E Stuart

Research output: Contribution to journal › Article › peer-review

Abstract

At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients. A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)? A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials? A3: Is the 2004 GCIG-recommended standard comparator arm still valid? A4: What is the role of modifying dose, schedule, and delivery of chemotherapy? A5: What role does surgery play today? Copyright © 2011 by IGCS and ESGO.

Original language	English
Pages (from-to)	756-762
Number of pages	6
Journal	International Journal of Gynecological Cancer
Volume	21
Issue number	4
DOIs	https://doi.org/10.1097/IGC.0b013e31821ce75d
Publication status	Published - May 2011

Keywords

Clinical trials
First line therapy
Ovarian cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/IGC.0b013e31821ce75d

Cite this

Thigpen, T., DuBois, A., McAlpine, J., DiSaia, P., Fujiwara, K., Hoskins, W., Kristensen, G., Mannel, R., Markman, M., Pfisterer, J., Quinn, M., Reed, N., MarieSwart, A., Berek, J., Colombo, N., Freyer, G., Gallardo, D., Plante, M., Poveda, A., ... Stuart, G. C. E. (2011). First-line therapy in ovarian cancer trials. International Journal of Gynecological Cancer, 21(4), 756-762. https://doi.org/10.1097/IGC.0b013e31821ce75d

@article{028c8526055f4d42b0fd2b457ade20c5,

title = "First-line therapy in ovarian cancer trials",

abstract = "At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients. A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)? A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials? A3: Is the 2004 GCIG-recommended standard comparator arm still valid? A4: What is the role of modifying dose, schedule, and delivery of chemotherapy? A5: What role does surgery play today? Copyright {\textcopyright} 2011 by IGCS and ESGO.",

keywords = "Clinical trials, First line therapy, Ovarian cancer",

author = "Tate Thigpen and Andreas DuBois and Jessica McAlpine and Philip DiSaia and Keiichi Fujiwara and William Hoskins and Gunnar Kristensen and Robert Mannel and Maurie Markman and Jacobus Pfisterer and Michael Quinn and Nick Reed and Ann MarieSwart and Jonathan Berek and Nicoletta Colombo and Gilles Freyer and Dolores Gallardo and Marie Plante and Andres Poveda and Lawrence Rubinstein and Monica Bacon and Henry Kitchener and Stuart, {Gavin C E}",

year = "2011",

month = may,

doi = "10.1097/IGC.0b013e31821ce75d",

language = "English",

volume = "21",

pages = "756--762",

journal = "International Journal of Gynecological Cancer",

issn = "1525-1438",

publisher = "Elsevier BV",

number = "4",

}

Thigpen, T, DuBois, A, McAlpine, J, DiSaia, P, Fujiwara, K, Hoskins, W, Kristensen, G, Mannel, R, Markman, M, Pfisterer, J, Quinn, M, Reed, N, MarieSwart, A, Berek, J, Colombo, N, Freyer, G, Gallardo, D, Plante, M, Poveda, A, Rubinstein, L, Bacon, M, Kitchener, H & Stuart, GCE 2011, 'First-line therapy in ovarian cancer trials', International Journal of Gynecological Cancer, vol. 21, no. 4, pp. 756-762. https://doi.org/10.1097/IGC.0b013e31821ce75d

TY - JOUR

T1 - First-line therapy in ovarian cancer trials

AU - Thigpen, Tate

AU - DuBois, Andreas

AU - McAlpine, Jessica

AU - DiSaia, Philip

AU - Fujiwara, Keiichi

AU - Hoskins, William

AU - Kristensen, Gunnar

AU - Mannel, Robert

AU - Markman, Maurie

AU - Pfisterer, Jacobus

AU - Quinn, Michael

AU - Reed, Nick

AU - MarieSwart, Ann

AU - Berek, Jonathan

AU - Colombo, Nicoletta

AU - Freyer, Gilles

AU - Gallardo, Dolores

AU - Plante, Marie

AU - Poveda, Andres

AU - Rubinstein, Lawrence

AU - Bacon, Monica

AU - Kitchener, Henry

AU - Stuart, Gavin C E

PY - 2011/5

Y1 - 2011/5

N2 - At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients. A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)? A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials? A3: Is the 2004 GCIG-recommended standard comparator arm still valid? A4: What is the role of modifying dose, schedule, and delivery of chemotherapy? A5: What role does surgery play today? Copyright © 2011 by IGCS and ESGO.

AB - At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients. A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)? A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials? A3: Is the 2004 GCIG-recommended standard comparator arm still valid? A4: What is the role of modifying dose, schedule, and delivery of chemotherapy? A5: What role does surgery play today? Copyright © 2011 by IGCS and ESGO.

KW - Clinical trials

KW - First line therapy

KW - Ovarian cancer

U2 - 10.1097/IGC.0b013e31821ce75d

DO - 10.1097/IGC.0b013e31821ce75d

M3 - Article

SN - 1525-1438

VL - 21

SP - 756

EP - 762

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

IS - 4

ER -

First-line therapy in ovarian cancer trials

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this